Amphastar Pharmaceuticals AMPH Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's accounts payable?
- Amphastar Pharmaceuticals (AMPH) reported accounts payable of $152.69M in Q1 2026.
- How has Amphastar Pharmaceuticals's accounts payable changed year-over-year?
- Amphastar Pharmaceuticals's accounts payable decreased by 13.2% year-over-year, from $175.94M to $152.69M.
- What is the long-term trend for Amphastar Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's accounts payable has grown at a 9.2% compound annual growth rate (CAGR), from $95.5M to $148.35M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.